Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically III patients

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 6, 2007, Pages 1967-1971

  Pena C ^a,b   Guzman A ^a   Suarez, C ^a   Dominguez, M A ^a   Tubau, F ^a   Pujol, M ^a   Gudiol, F ^a   Ariza, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; MEROPENEM; TICARCILLIN; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONFIDENCE INTERVAL; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GASTROINTESTINAL TRACT; GENOTYPE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR; THROAT CULTURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; CARBAPENEMS; CARRIER STATE; CRITICAL ILLNESS; ENDEMIC DISEASES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMIPENEM; INCIDENCE; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PHARYNX; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECTUM; RISK FACTORS;

EID: 34250220334     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01483-06     Document Type: Article

References (26)

1. Alyaseen, S. A., K. E. Piper, M. S. Rouse, J. M. Steckelberg, and R. Patel. 2005. Selection of cross resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime. Antimicrob. Agents Chemother. 49:2543-2545.
2. Bayer, A. S., L. Hirano, and J. Yih. 1988. Development of β-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob. Agents Chemother. 32:231-235.
3. Bergmans, D. C., M. J. Bonten, F. H. van Tiel, C. A. Gaillard, S. van der Geest, R. M. Wilting, P. W. de Leeuw, and E. E. Stobberingh. 1998. Cross-colonization with Pseudomonas aeruginosa of patients in an intensive care unit. Thorax 53:1053-1058.
4. Bertrand, X., M. Thouverez, D. Talon, A. Boillot, G. Capellier, C. Floriot, and J. P. Helias. 2001. Endemicity, molecular diversity and colonization routes of Pseudomonas aeruginosa in intensive care units. Intensive Care Med. 27:1263-1268.
5. Bonten, M. J., S. Slaughter, A. W. Ambergen, M. K. Hayden, J. van Voorhis, C. Nathan, and R. A. Weinstein. 1998. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci. An important infection control variable. Arch. Intern. Med. 158:1127-1132.
6. Bonten, M. J., D. C. Bergmans, H. Speijer, and E. E. Stobberingh. 1999. Characteristic of polyclonal endemicity of Pseudomonas aeruginosa colonization in intensive care units. Implications for infection control. Am. J. Respir. Crit. Care Med. 160:1212-1219.
7. Carmeli, Y., N. Troillet, G. M. Eliopoulos, and M. H. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.
8. Defez, C., P. Fabbro-Peray, N. Bouziges, A. Gouby, A. Mahamat, J. P. Daurés, and A. Sotto. 2004. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J. Hosp. Infect. 57:209-216.
9. Foca, M., K. Jakob, S. Whittier, P. Della Latta, S. Factor, D. Rubenstein, and L. Saiman. 2000. Endemic Pseudomonas aeruginosa infection in a neonatal intensive care unit. N. Engl. J. Med. 343:695-700.
10. Gruner, E., A. Kropec, J. Huebner, M. Altwegg, and F. Pashner. 1993. Ribotyping of Pseudomonas aeruginosa strains isolated from surgical intensive care patient. J. Infect. Dis. 167:1216-1220.
11. Hanberger, H., J. A. García-Rodriguez, M. Gobernado, H. Goossens, L. E. Nilsson, M. J. Struelens, and the French and Portuguese ICU Study Groups. 1999. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. JAMA 281:67-71.
12. Harris, A. D., D. Smith, J. A. Johnson, D. D. Bradham, and M. C. Roghmann. 2002. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin. Infect. Dis. 34:340-345.
13. Hsu, D. I., M. P. Okamoto, R. Murthy, and A. Wong-Beringer. 2005. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J. Antimicrob. Chemother. 55:535-541.
14. Le Gall, J. R., P. Loirat, A. Alperovitch, P. Glaser, C. Granthil, D. Mathieu, P. Mercier, R. Thomas, and D. Villers. 1984. A simplified acute physiologic score for ICU patients. Crit. Care Med. 12:975-977.
15. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
16. Olson, B., R. A. Weinstein, C. Nathan, W. Chamberlin, and S. A. Kabins. 1984. Epidemiology of endemic Pseudomonas aeruginosa: why infection control efforts have failed. J. Infect. Dis. 150:808-816.
17. Ortega, B., A. B. J. Groeneveld, and C. Schultsz. 2004. Endemic multidrug-resistant Pseudomonas aeruginosa in critically ill patients. Infect. Control Hosp. Epidemiol. 25:825-831.
18. Murthy, S. K., A. L. Baltch, R. P. Smith, E. K. Desjardin, M. C. Hammer, J. V. Conroy, and P. B. Michelsen. 1989. Oropharyngeal and fecal carriage of Pseudomonas aeruginosa in hospital patients. J. Clin. Microbiol. 27:35-40.
19. National Committee for Clinical Laboratory Standards. 2001. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Document M7-A4. National Committee for Clinical Laboratory Standards, Villanova, PA.
20. Nordic Council on Medicines. 1994. Nordic statistics on medicines. Nordic drug index with classification and defined daily doses. Nordic Council on Medicines, Uppsala, Sweden.
21. Paramythiotou, E., J. C. Lucet, J. F. Timsit, D. Vanjak, C. Paugam-Burtz, J. L. Trouillet, S. Belloc, N. Kassis, A. Karabinis, and A. Andremont. 2004. Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin. Infect: Dis. 38:670-677.
22. Reuter, S., A. Sigge, H. Wiedeck, and M. Trautmann. 2002. Analysis of transmission pathways of Pseudomonas aeruginosa between patients and tap water outlets. Crit. Care Med. 30:2222-2228.
23. Smith, C. L., and C. R. Cantor. 1987. Purification, specific fragmentation, and separation of large DNA molecules. Methods Enzymol. 155:449-467.
24. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
25. Troillet, N., M. H. Samore, and Y. Carmeli. 1997. Imipenem resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098.
26. Vallés, J., D. Mariscal, P. Cortés, P. Coll, A. Villagrá, E. Diaz, A. Artigas, and J. Rello. 2004. Patterns of colonization by Pseudomonas aeruginosa in intubated patients: a 3-year prospective study of 1,607 isolates by pulsed-field gel electrophoresis with implications for prevention of ventilator-associated pneumonia. Intensive Care Med. 30:1768-1775.